A systematic review published in the International Journal of Medical Science and Health Research discusses a number of advanced and add-on therapies for neonatal jaundice that are more effective than conventional phototherapy alone.
Jaundice is very common in patients with hemolytic disease of the fetus and newborn (HDFN). The condition results from a buildup of bilirubin, also known as hyperbilirubinemia, and leads to yellowing of the eyes and skin.
Though phototherapy is the standard treatment for jaundice, researchers have been exploring new tools that have the potential to improve efficacy and reduce the risk of side effects.
The authors included 20 studies that compared traditional phototherapy to newer methods among neonates. Of these, 10 assessed modifications to phototherapy intensity, duration and device. Seven assessed the addition of adjunct therapies such as zinc, albumin, clofibrate, intravenous immunoglobulin (IVIG), silymarin and Clostridium butyricum. Three assessed different light sources including sunlight, reflective light and fiber optics.
Read more about HDFN treatment and care
The findings revealed that alternative methods were typically as effective as or even more effective than conventional phototherapy in reducing bilirubin levels. The same was true for treatment duration. Albumin, however, showed limited benefits and was relatively expensive.
The included studies also demonstrated that these advanced methods do not carry increased risks to the patient.
Many papers agreed that increasing the surface area exposed to treatment improves efficacy. However, it remains unclear whether intermittent phototherapy provides a significant benefit over continuous exposure.
The major barriers to implementation included price and monitoring. In health care settings with limited resources, filtered sunlight emerged as a cost-effective option. Staff education, drug and equipment availability and infection control were other frequently mentioned difficulties.
“The field of neonatal jaundice management is evolving rapidly, with numerous effective strategies available,” the authors wrote. “The findings underscore the need for clinicians to tailor treatment strategies based on the severity of jaundice, the specific clinical context (e.g., presence of hemolysis), and the resources available.”
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
